Clinical Trials Directory

Trials / Completed

CompletedNCT03642600

The Gut Microbiome in Women With Polycystic Ovary Syndrome

Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role?

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Testing two different strategies for weight loss intervention and revealing possible changes in composition of gut microbiota, in order to provide more insight in the effect of dietary changes and weight loss treatments on gut microbiome in overweight and obese women with polycystic ovary syndrome (PCOS). The two strategies are: * dietary advice plus myo-inositol and folic acid * dietary advice plus liraglutide, glucagon-like peptide-1 (GLP-1) receptor agonist Primary outcome will be weight loss. Secondary outcomes are longitudinal changes in clinical features associated with PCOS and metabolic syndrome, longitudinal changes in gut microbiome with interventions. Subjects will be treated during 16 weeks and follow-up will take 16 weeks after stop of treatment.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTdietary advice plus myo-inositol and folic aciddietary advice and lifestyle interventions and myo-inositol
DRUGdietary advice plus Liraglutide Pen Injectordietary advice and lifestyle interventions and liraglutide pen injector

Timeline

Start date
2019-02-28
Primary completion
2020-02-01
Completion
2020-07-03
First posted
2018-08-22
Last updated
2020-11-04

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03642600. Inclusion in this directory is not an endorsement.